. 2001 May;51(5):429–435. doi: 10.1046/j.1365-2125.2001.01358.x

Table 2.

Statistical comparison of anastrozole and placebo treatment groups to assess the effects of concomitant administration of anastrozole on the anticoagulant activity of warfarin.

	Anastrozole		Placebo
Parameter	n	glsmean	n	glsmean	Treatment effect^a	95% CI	P value
PT (s)
Pre-dose (day 3)^b	16	11.56	15	11.45	1.010	0.984,1.037	0.442
AUC(8,94 h)	16	17.45	15	18.36	0.951	0.860,1.052	0.299
166 h^b	16	11.27	15	11.31	1.023	0.987,0.983	0.015
240 h^b	16	11.56	15	11.31	1.023	0.987,1.059	0.193
aPTT (s)
Pre-dose (day 3)^b	16	30.07	15	29.52	1.019	0.987,1.052	0.233
AUC(8,94 h)	16	34.96	15	36.07	0.969	0.919,1.023	0.237
166 h^b	16	29.43	14^c	31.72	0.928	0.889,0.968	0.002
240 h^b	16	29.94	15	29.74	1.007	0.968,1.047	0.722
TT (s)
Pre-dose (day 3)^b	16	18.64	15	18.23	1.023	0.991,1.055	0.148
AUC(8,94 h)	16	18.86	15	18.68	1.010	0.979,1.042	0.505
166 h^b	16	18.72	14^c	19.05	0.983	0.935,1.034	0.474
240 h^b	16	19.06	15	18.75	1.017	0.980,1.054	0.350
Factor VII (%)
Pre-dose (day 3)^b	16	109.59	15	103.34	1.060	0.925,1.215	0.366
AUC(8,22 h)	16	51.09	15	46.04	1.110	0.982,1.254	0.088
AUC(22,94 h)	16	30.94	15	28.67	1.079	1.908,1.284	0.355
166 h^b	16	108.96	15	98.72	1.104	0.970,1.256	0.123
240 h^b	16	97.81	15	107.26	0.912	0.821,1.012	0.079

glsmean of the anastrozole phase divided by the glsmean of the placebo phase.

times relate to dosing of warfarin.

value not recorded for subject 0006. CI: confidence interval, PT: prothrombin time, aPTT: activated thromboplastin time, TT: thrombin time, AUC: area under the pharmacodynamic-time curve, glsmean: geometric least squares mean.